The FDA has granted accelerated approval to aducanumab (Aduhelm) for the treatment of Alzheimer disease with an overly broad label. The decision disregarded key aspects of scientific process and risks eroding public trust in research, regulatory science and the FDA.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Proxies of Trustworthiness: A Novel Framework to Support the Performance of Trust in Human Health Research
Journal of Bioethical Inquiry Open Access 29 March 2024
-
Long-term normalization of calcineurin activity in model mice rescues Pin1 and attenuates Alzheimer’s phenotypes without blocking peripheral T cell IL-2 response
Alzheimer's Research & Therapy Open Access 17 October 2023
-
3D bioprinting patient-derived induced pluripotent stem cell models of Alzheimer’s disease using a smart bioink
Bioelectronic Medicine Open Access 24 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cavazzoni, P. FDA’s Decision to Approve New Treatment for Alzheimer’s Disease. FDA https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease (2021).
McGinley, L. Two members of an FDA advisory committee quit after approval of controversial Alzheimer’s drug. Washington Post https://www.washingtonpost.com/health/2021/06/09/alzheimers-drug-controversy/ (2021).
Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) meeting. Virtual meeting. Friday, November 6, 2020. FDA https://www.fda.gov/media/145691/download (2020).
Food and Drug Administration. Aducanumab for the treatment of Alzheimer’s disease: clinical overview of efficacy. FDA https://www.fda.gov/media/143504/download (2020).
CNBC. First on CNBC: CNBC transcript: Biogen CEO Michel Vounatsos speaks with CNBC’s “Power Lunch” today. CNBC https://www.cnbc.com/2021/06/07/first-on-cnbc-cnbc-transcript-biogen-ceo-michel-vounatsos-speaks-with-cnbcs-power-lunch-today.html (2021).
Mintun, M. A. et al. Donanemab in early Alzheimer’s disease. N. Engl. J. Med. 384, 1691–1704 (2021).
Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res. Ther. 13, 80 (2021).
Kesselheim, A. S. Letter, Twitter https://twitter.com/akesselheim/status/1403675166803169283 (Kesselheim to Woodcock, 10 June 2021).
Manchin, J. Letter, manchin.senate.gov https://www.manchin.senate.gov/imo/media/doc/letter_to_white_house_regarding_fda.pdf?cb (Manchin to Biden, 17 June 2021).
Eli Lilly and Company. Lilly’s donanemab receives U.S. FDA’s Breakthrough Therapy designation for treatment of Alzheimer’s disease. Lilly Investors https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-receives-us-fdas-breakthrough-therapy (2021).
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding author
Ethics declarations
Competing interests
J.K. is a site investigator for studies sponsored by Biogen, Eisai and Eli Lilly. J.D.G. receives research support from Biogen, Eisai, Eli Lilly and Genentech; and consulting fees from Cogniciti, Flint Rehab and SiteRx.
Rights and permissions
About this article
Cite this article
Karlawish, J., Grill, J.D. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. Nat Rev Neurol 17, 523–524 (2021). https://doi.org/10.1038/s41582-021-00540-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-021-00540-6
This article is cited by
-
Proxies of Trustworthiness: A Novel Framework to Support the Performance of Trust in Human Health Research
Journal of Bioethical Inquiry (2024)
-
Long-term normalization of calcineurin activity in model mice rescues Pin1 and attenuates Alzheimer’s phenotypes without blocking peripheral T cell IL-2 response
Alzheimer's Research & Therapy (2023)
-
3D bioprinting patient-derived induced pluripotent stem cell models of Alzheimer’s disease using a smart bioink
Bioelectronic Medicine (2023)
-
Stem Cell-derived Extracellular Vesicles: A Promising Nano Delivery Platform to the Brain?
Stem Cell Reviews and Reports (2023)
-
A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease
Science and Engineering Ethics (2023)